PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of ijpsychHomeCurrent issueInstructionsSubmit article
 
Indian J Psychiatry. 2003 Jan-Mar; 45(1): 30–35.
PMCID: PMC2951537

Risk Factors in Neuroleptic Malignant Syndrome

Abstract

Neuroleptic malignant syndrome (NMS) is an uncommon but potentially serious idiosyncratic response to neuroleptic antipsychotics. It usually affects young males, but the risk has been seen to increase with certain factors including the administration practices of antipsychotic neuroleptics in these individuals. Even though no predictors for NMS are yet known, this article highlights the findings on certain risk factors as seen from a series of fifteen patients who developed NMS. Cautious use of neuroleptics in those at risk, early recognition and institution of immediate management is important.

Keywords: neuroleptic, malignant syndrome, risk factors

Full Text

The Full Text of this article is available as a PDF (309K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Addonizio G, Susman VL, Roth SD. Symptoms of neuroleptic malignant syndrome in 82 consecutive inpatients. Am J Psychiatry. 1986 Dec;143(12):1587–1590. [PubMed]
  • Berardi D, Amore M, Keck PE, Jr, Troia M, Dell'Atti M. Clinical and pharmacologic risk factors for neuroleptic malignant syndrome: a case-control study. Biol Psychiatry. 1998 Oct 15;44(8):748–754. [PubMed]
  • Caroff SN, Mann SC. Neuroleptic malignant syndrome. Med Clin North Am. 1993 Jan;77(1):185–202. [PubMed]
  • Ebadi M, Pfeiffer RF, Murrin LC. Pathogenesis and treatment of neuroleptic malignant syndrome. Gen Pharmacol. 1990;21(4):367–386. [PubMed]
  • Gelenberg AJ, Bellinghausen B, Wojcik JD, Falk WE, Sachs GS. A prospective survey of neuroleptic malignant syndrome in a short-term psychiatric hospital. Am J Psychiatry. 1988 Apr;145(4):517–518. [PubMed]
  • Gleason PP, Conigliaro RL. Neuroleptic malignant syndrome with risperidone. Pharmacotherapy. 1997 May-Jun;17(3):617–621. [PubMed]
  • Gurrera RJ. Sympathoadrenal hyperactivity and the etiology of neuroleptic malignant syndrome. Am J Psychiatry. 1999 Feb;156(2):169–180. [PubMed]
  • Harsch HH. Neuroleptic malignant syndrome: physiological and laboratory findings in a series of nine cases. J Clin Psychiatry. 1987 Aug;48(8):328–333. [PubMed]
  • Hasan S, Buckley P. Novel antipsychotics and the neuroleptic malignant syndrome: a review and critique. Am J Psychiatry. 1998 Aug;155(8):1113–1116. [PubMed]
  • Heiman-Patterson TD. Neuroleptic malignant syndrome and malignant hyperthermia. Important issues for the medical consultant. Med Clin North Am. 1993 Mar;77(2):477–492. [PubMed]
  • Hermesh H, Aizenberg D, Weizman A, Lapidot M, Mayor C, Munitz H. Risk for definite neuroleptic malignant syndrome. A prospective study in 223 consecutive in-patients. Br J Psychiatry. 1992 Aug;161:254–257. [PubMed]
  • Itoh H, Ohtsuka N, Ogita K, Yagi G, Miura S, Koga Y. Malignant neuroleptic syndrome--its present status in Japan and clinical problems. Folia Psychiatr Neurol Jpn. 1977;31(4):559–576. [PubMed]
  • Iwahashi K. CYP2D6 genotype and possible susceptibility to the neuroleptic malignant syndrome. Biol Psychiatry. 1994 Dec 1;36(11):781–782. [PubMed]
  • Keck PE, Jr, Sebastianelli J, Pope HG, Jr, McElroy SL. Frequency and presentation of neuroleptic malignant syndrome in a state psychiatric hospital. J Clin Psychiatry. 1989 Sep;50(9):352–355. [PubMed]
  • Keck PE, Jr, Pope HG, Jr, Cohen BM, McElroy SL, Nierenberg AA. Risk factors for neuroleptic malignant syndrome. A case-control study. Arch Gen Psychiatry. 1989 Oct;46(10):914–918. [PubMed]
  • Levenson JL. Neuroleptic malignant syndrome. Am J Psychiatry. 1985 Oct;142(10):1137–1145. [PubMed]
  • Modestin J, Toffler G, Drescher JP. Neuroleptic malignant syndrome: results of a prospective study. Psychiatry Res. 1992 Dec;44(3):251–256. [PubMed]
  • Ram A, Cao Q, Keck PE, Jr, Pope HG, Jr, Otani K, Addonizio G, McElroy SL, Kaneko S, Redlichova M, Gershon ES, et al. Structural change in dopamine D2 receptor gene in a patient with neuroleptic malignant syndrome. Am J Med Genet. 1995 Jun 19;60(3):228–230. [PubMed]
  • Reddig S, Minnema AM, Tandon R. Neuroleptic malignant syndrome and clozapine. Ann Clin Psychiatry. 1993 Mar;5(1):25–27. [PubMed]
  • Rosebush P, Stewart T. A prospective analysis of 24 episodes of neuroleptic malignant syndrome. Am J Psychiatry. 1989 Jun;146(6):717–725. [PubMed]
  • Sachdev P, Kruk J, Kneebone M, Kissane D. Clozapine-induced neuroleptic malignant syndrome: review and report of new cases. J Clin Psychopharmacol. 1995 Oct;15(5):365–371. [PubMed]
  • Shalev A, Hermesh H, Munitz H. Mortality from neuroleptic malignant syndrome. J Clin Psychiatry. 1989 Jan;50(1):18–25. [PubMed]
  • Spivak B, Weizman A, Wolovick L, Hermesh H, Tyano S, Munitz H. Neuroleptic malignant syndrome during abrupt reduction of neuroleptic treatment. Acta Psychiatr Scand. 1990 Feb;81(2):168–169. [PubMed]
  • Velamoor VR, Norman RM, Caroff SN, Mann SC, Sullivan KA, Antelo RE. Progression of symptoms in neuroleptic malignant syndrome. J Nerv Ment Dis. 1994 Mar;182(3):168–173. [PubMed]

Articles from Indian Journal of Psychiatry are provided here courtesy of Medknow Publications